PURE Bioscience Reports Fourth Quarter and Year End Results

SAN DIEGO, Calif., OCT. 15, 2008 – PURE Bioscience (NASDAQ: PURE), creators of the patented antimicrobial, silver dihydrogen citrate (SDC), today reported revenues for the fiscal year ended July 31, 2008 of $1,487,500, which increased more than 340% compared with $336,400 in the prior fiscal year.  The Company reported a loss from operations before taxes of $(6,540,300), or $(0.24) per share, compared with a loss of $(4,654,900), or $(0.19) per share, in the prior year. 

Included in the loss from operations before taxes for the fiscal year ended July 31, 2008 was $2,638,000 of non-cash expense, including stock-based compensation, amortization and depreciation, compared with $1,796,900 of such non-cash expense for the year ended July 31, 2007.

During the fourth quarter of its fiscal year, PURE announced new distribution agreements with Orchem Corporation and DuraBan International, two recognized organizations with established sales channels which will shortly begin to market SDC-based products.  In addition, the Company announced that its distribution partner in Brazil had received approval to manufacture and sell SDC-based disinfectant.  Finally, PURE entered into an agreement with FTA Therapeutics, LLC for the development and licensing of additional silver dihydrogen citrate (SDC)-based products for human use.  FTA has already begun initial formulation and clinical projects for FDA-regulated dermatology, wound care and medical biofilm control products containing SDC.

Earlier in the year, the company signed an agreement with Rockline Industries, Inc., for North American distribution of PURE’s ready-to-use disinfectant product and for the development and North American distribution of wipes products as well as new disinfectant, sanitizer and preservative products containing SDC.  Rockline is the market leader in the manufacture and distribution of wipes.  In addition, PURE received approval for expanded efficacy claims by the EPA and broadened its patent portfolio; and our common stock commenced trading on the Nasdaq exchange and was added as a component of the Russell Microcap Index.

“During fiscal 2008, we strengthened our competitive position and built upon our private label distribution network culminating in an outstanding fourth quarter in which we posted more than $820,000 in revenue,” said Michael L. Krall, President and CEO of Pure Bioscience.  “PURE established and continues to make important strides toward finalizing additional contracts with major market players for the integration of SDC into third party products, including a new partnership with a respected leader for the development of FDA-regulated SDC products.

“It is important to note that virtually all of our initiatives within major markets and with world-class partners remain under continuing discussion and negotiation.  Furthermore, we have identified a number of large new markets for SDC for agriculture and water applications, particularly within growing developing countries around the world.  Finally, regulatory and legislative changes, as well as consumer and competitive pressures are driving companies to explore, review and adopt “green” and environmentally favorable solutions like SDC, the first new anti-microbial approved by the EPA in over thirty years.

“The size of potential markets and the breadth of applications for our technology continue to grow,” concluded Mr. Krall.  “From our presentations and meetings across various sectors and country borders, with current, pending and potential industry-leading partners, I have never been more encouraged and confident in the soundness of our strategy, the focus of our execution and the enormous opportunities for growth and success for PURE Bioscience.”

The Company has scheduled a conference call to present year end-results on Thursday, October 16, 2008 at 4:30 PM ET.  The conference call will consist of prepared remarks from management and will be available over the Internet via live web cast at www.purebio.com. Shareholders can submit questions for the conference call via e mail through the investor section of the company web page at www.purebio.com.

The conference call will also be accessible by telephone at (800) 309-1352 (no passcode required) and participants are advised to dial-in at least five minutes before the scheduled start time. The replay of the conference call will be available for seven days by telephone at (888) 203-1112 or (719) 457-0820 using passcode 3067874. The webcast will be archived for a period of 90 days at www.purebio.com

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety.  Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds.  As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.  PURE is headquartered in El Cajon, California (San Diego metropolitan area).  Additional information on PURE is available at www.purebio.com. 

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.